Parisian Beauty: Intensifying Competition Makes Scale Key
The beauty market sustains above-average growth, but competition is accelerating, elevating scale as a decisive moat. Premium continues to outperform mass; the category’s boundaries are expanding toward supplements and aesthetics. We see Intercos as the best way to play rising innovation intensity. We remain Equal-weight on L’Oréal and Estée Lauder — current valuations reflect resilience but offer limited upside — and Underweight Beiersdorf, whose scale disadvantage risks market share losses.
Feedback from L’Oréal, Estée Lauder, and Intercos confirms that luxury beauty, especially the top price tier, remains robust. China perfectly illustrates the divergence: luxury expanding mid-to-high single digits while mass stays negative. L’Oréal’s CFO highlighted strong US momentum and surprisingly resilient European demand, driven partly by geographic expansion of Mixa. This premium bias shelters top players but raises the cost of competing in mass channels.
Innovation cycles are shortening. L’Oréal’s FY25 ‘beauty stimulus plan’ led the market, but Estée and Intercos now signal that peers are catching up, with a notable ramp in new product introductions from Q2 2026. The consequence: market share captured in H1 2026 will be harder to defend in H2, and marketing spend must rise. For contract manufacturers like Intercos, this translates directly into higher demand for agile R&D and scaled production.
The addressable market is broadening. BCG/WWD research on “Optimizers” — 15 million US consumers (~6% of adults) spending nearly $3,000 annually — reveals that only one-third goes to traditional beauty. The remainder splits between aesthetic procedures and supplements (prescription skincare, GLP-1, longevity clinics). These heavy users adopt premium-grade skincare and are high-propensity supplement buyers. L’Oréal’s Phase 2 R&D joint venture with Galderma exemplifies the blurring of beauty and wellness. A larger pie also attracts new entrants, making scale and integrated R&D capabilities more critical than ever.
Risks center on: (1) geopolitical shocks eroding consumer sentiment; (2) a wave of H2 launches and marketing wars compressing margins; (3) persistent mass-market weakness in China. These pressures are manageable for scaled players but disproportionately hurt smaller brands.
In this environment, Intercos (ICOS.MI) stands out as an innovation accelerator without direct brand risk. We hold Equal-weight on OR.PA and EL: rising competitive intensity and marketing load cap margin expansion. Beiersdorf (BEI.DE), lacking the scale to sustain innovation and defend share, is our Underweight call. The beauty industry’s widening perimeter rewards those with sizeable R&D engines and distribution breadth.